CG0070 Plus Pembrolizumab Produces Durable Responses in BCG-Unresponsive NMIBC
The cancer-selective oncolytic adenovirus cretostimogene grenadenorepvec (CG0070) plus pembrolizumab (Keytruda) elicited synergistic activity leading to durable responses and could provide an effective treatment alternative for patients with Bacillus Calmette-Guérin (BCG)–unresponsive, carcinoma in situ (CIS)–containing non–muscle invasive bladder cancer (NMIBC) who cannot undergo radical cystectomy, according to Roger Li, MD. The phase 2, single-arm CORE-001 trial … [Read more…]